Q1 2016 13F Holders as of 3/31/2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
15.6M
-
Shares change
-
-597K
-
Total reported value, excl. options
-
$264M
-
Value change
-
-$13.1M
-
Put/Call ratio
-
0.61
-
Number of buys
-
49
-
Number of sells
-
-43
-
Price
-
$16.91
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2016
126 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2016.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.6M shares
of 207M outstanding shares and own 7.53% of the company stock.
Largest 10 shareholders include Aisling Capital LLC (1.64M shares), Pentwater Capital Management LP (1.42M shares), FMR LLC (1.18M shares), COLUMBUS CIRCLE INVESTORS (1.12M shares), BB BIOTECH AG (1.01M shares), DISCOVERY CAPITAL MANAGEMENT, LLC / CT (806K shares), WASATCH ADVISORS INC (759K shares), VANGUARD GROUP INC (737K shares), Sarissa Capital Management LP (633K shares), and Voya Investment Management LLC (632K shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.